Concert Pharmaceuticals's competitors

Concert Pharmaceuticals's competitors include ChemoCentryx, Inspyr Therapeutics, Palatin Technologies and RespireRx Pharmaceuticals
Add company...
Concert Pharmaceuticals
Concert Pharmaceuticals is a biotechnology company utilizing deuterium to develop novel medical candidates.
ChemoCentryx
ChemoCentryx develops orally-administered small molecule therapeutics that target chemokine receptors and related chemo-attractants.
Inspyr Therapeutics
Inspyr Therapeutics is a development-stage pharmaceutical company focused on therapeutics that deliver a cancer-destroying drug directly to the tumor or its supporting environment, the tumor vasculature.
Palatin Technologies
Palatin Technologies is a biopharmaceutical company, developing targeted, receptor-specific peptide therapeutics for the treatment of various diseases.
RespireRx Pharmaceuticals
RespireRx Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery and development of novel drug therapies for the treatment of sleep apnea, drug-induced respiratory depression and other brain-mediated breathing disorders.
Founding Date
Founding Date
2006
Founding Date
1997
Founding Date
1903
Founding Date
1986
Founding Date
1988
Type
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Tags
Locations
Locations
Lexington, US HQ
Locations
Mountain View, US HQ
Locations
Westlake Village, US HQ
Locations
Cranbury, US HQ
Locations
Glen Rock, US HQ
Employees
Employees
69
Employees
62
Employees
2
Employees
22
Employees
1
Valuation ($)
Valuation ($)
441.9 m
Valuation ($)
529.4 m
Valuation ($)
699.5 k
Valuation ($)
247.3 m
Valuation ($)
2.3 m
Facebook likes
Facebook likes
N/A
Facebook likes
N/A
Facebook likes
1.4 k
Facebook likes
36
Facebook likes
N/A
Twitter followers
Twitter followers
N/A
Twitter followers
N/A
Twitter followers
401
Twitter followers
419
Twitter followers
N/A

Financial

Revenue (est.)
Revenue (est.)
$143.9m (FY, 2017)
Revenue (est.)
$82.5m (FY, 2017)
Revenue (est.)
N/A
Revenue (est.)
N/A
Revenue (est.)
N/A
Net income
Net income
$95.6m (FY, 2017)
Net income
$17.9m (FY, 2017)
Net income
($3.6m) (FY, 2016)
Net income
($51.7m) (FY, 2016)
Net income
($4.3m) (FY, 2017)
For sources of this data, please see the company profileDownload Excel

View company profiles